{
    "clinical_study": {
        "@rank": "63594", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Experimental", 
                "description": "LF formulation of IMVAMUNE\u00ae 2 doses of 1 x 10E8 TCID50, s.c., 4 weeks apart"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Experimental", 
                "description": "FD formulation of IMVAMUNE\u00ae 2 doses of 1 x 10E8 TCID50, s.c., 4 weeks apart"
            }
        ], 
        "brief_summary": {
            "textblock": "A randomized, double-blind, multicenter Phase II trial to compare the immunogenicity and\n      safety of a liquid-frozen and a freeze-dried formulation of IMVAMUNE (MVA-BN\u00ae) smallpox\n      vaccine in vaccinia-na\u00efve healthy subjects"
        }, 
        "brief_title": "A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN\u00ae) Smallpox Vaccine in Vaccinia-na\u00efve Healthy Subjects", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Smallpox", 
        "condition_browse": {
            "mesh_term": [
                "Smallpox", 
                "Vaccinia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria\n\n          1. Male and female subjects, 18-55 years of age\n\n          2. The subject has read, signed and dated informed consent form, having been advised of\n             the risks and benefits of the trial in a language understood by the subject and prior\n             to performance of any trial specific procedures and has signed the Health Insurance\n             Portability and Accountability Act (HIPAA) authorization form\n\n          3. Body Mass Index (BMI)  \u2265 18.5 and < 35\n\n          4. Women of childbearing potential (WOCBP) must have used an acceptable method of\n             contraception for 30 days prior to the first vaccination, must agree to use an\n             acceptable method of contraception during the trial, and must avoid becoming pregnant\n             for at least 28 days after the last vaccination. A woman is considered of\n             childbearing potential unless post-menopausal or with a history of hysterectomy.\n             (Acceptable contraception methods are restricted to abstinence, barrier\n             contraceptives, intrauterine contraceptive devices or licensed hormonal products)\n\n          5. WOCBP must have a negative serum pregnancy test at screening (SCR) and a negative\n             urine pregnancy test within 24 hours prior to each vaccination\n\n          6. White blood cells \u2265 2500/mm3 and < ULN\n\n          7. Absolute neutrophil count (ANC) within normal limits\n\n          8. Hemoglobin within normal limits\n\n          9. Platelets within normal limits\n\n         10. Adequate renal function defined as a calculated Creatinine Clearance (CrCl) > 60\n             ml/min as estimated by the Cockcroft-Gault equation:\n\n               -  For men: (140 - age in years) x (body weight in kg) \u00f7 (serum creatinine in mg/dl\n                  x 72) = CrCl (ml/min)\n\n               -  For women: multiply the result by 0.85 = CrCl (ml/min)\n\n         11. Adequate hepatic function defined as:\n\n               -  Total bilirubin \u2264 1.5 x upper limit of normal (ULN) in the absence of other\n                  evidence of significant liver disease\n\n               -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline\n                  phosphatase < 1.5 x ULN\n\n         12. Troponin I < 2 x ULN\n\n         13. Electrocardiogram (ECG) without clinically significant findings, e.g. any kind of\n             atrioventricular or intraventricular conditions or blocks such as complete left or\n             right bundle branch block, AV node block, QTc or PR prolongation, premature atrial\n             contractions or other atrial arrhythmia, sustained ventricular arrhythmia, two\n             premature ventricular contractions (PVC) in a row, ST elevation consistent with\n             ischemia\n\n        Exclusion criteria\n\n          1. Typical vaccinia scar\n\n          2. Known or suspected history of smallpox vaccination\n\n          3. History of vaccination with any poxvirus-based vaccine\n\n          4. US Military service before 1991 or after January 2003\n\n          5. Pregnant or breast-feeding women\n\n          6. Uncontrolled serious infection, i.e. not responding to antimicrobial therapy\n\n          7. History of any serious medical condition, which in the opinion of the investigator\n             would compromise the safety of the subject or would limit the subject's ability to\n             complete the trial in the opinion of the investigator\n\n          8. History of or active autoimmune disease,  persons with vitiligo or thyroid disease\n             taking thyroid hormone replacement are not excluded\n\n          9. Known or suspected impairment of immunologic function including, but not limited to,\n             clinically significant liver disease, diabetes mellitus, moderate to severe kidney\n             impairment\n\n         10. History of malignancy, other than squamous cell or basal cell skin cancer, unless\n             there has been surgical excision that is considered to have achieved cure. Subjects\n             with history of skin cancer must not be vaccinated at the previous tumor site\n\n         11. History or clinical manifestation of clinically significant and severe hematological,\n             pulmonary, central nervous, cardiovascular or gastrointestinal disorders\n\n         12. Clinically significant mental disorder not adequately controlled by medical treatment\n\n         13. History of coronary heart disease, myocardial infarction, angina, congestive heart\n             failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood\n             pressure, or any other heart condition under the care of a doctor\n\n         14. History of an immediate family member (father, mother, brother, or sister) who has\n             had onset of ischemic heart disease before the age of 50 years\n\n         15. Twenty percent or greater risk of developing a myocardial infarction or coronary\n             death within the next 10 years using the National Cholesterol Education Program's\n             Risk Assessment Tool: http://hin.nhlbi.nih.gov/atpiii/calculator.asp NOTE: This\n             criterion applies only to subjects 20 years of age and older\n\n         16. Active or history of chronic alcohol abuse and/or intravenous and/or nasal drug abuse\n             (within the past 6 months)\n\n         17. Known allergy to IMVAMUNE\u00ae vaccine and its constituents, e.g.\n             tris(hydroxymethyl)-amino methane, including known allergy to egg or aminoglycoside\n             (gentamycin)\n\n         18. History of anaphylaxis or severe allergic reaction to any vaccine\n\n         19. Acute disease (illness with or without a fever) at the time of enrollment\n\n         20. Body Temperature \u2265 100.4\u00b0F (38.0\u00b0C) at the time of enrollment\n\n         21. Having received any vaccinations or planned vaccinations with a live vaccine within\n             30 days prior or after trial vaccination\n\n         22. Having received any vaccinations or planned vaccinations with a killed vaccine within\n             14 days prior or after trial vaccination\n\n         23. Chronic systemic administration (defined as more than 14 days) of > 5 mg prednisone\n             (or equivalent)/day or any other immune-modifying drugs during a period starting from\n             three months prior to administration of the vaccine and ending at last physical trial\n             visit (Visit 5)\n\n         24. Post organ transplant subjects whether or not receiving chronic immunosuppressive\n             therapy\n\n         25. Administration or planned administration of immunoglobulins and/or any blood products\n             during a period starting from three months prior to administration of the vaccine and\n             ending at last physical trial visit (Visit 5)\n\n         26. Use of any investigational or non-registered drug or vaccine other than the trial\n             vaccine within 30 days preceding the first dose of the trial vaccine or planned\n             administration of such a drug during the trial period (with the day of the FU call\n             being considered the last day of the trial period).\n\n         27. Trial personnel"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "650", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01668537", 
            "org_study_id": "POX-MVA-027"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group 1", 
                "intervention_name": "LF formulation of IMVAMUNE\u00ae", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Group 2", 
                "intervention_name": "FD formulation of IMVAMUNE\u00ae", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 13, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "South Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33143"
                    }, 
                    "name": "Miami Research Associates"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lenexa", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66219"
                    }, 
                    "name": "PRA"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40536"
                    }, 
                    "name": "University of Kentucky"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Multicenter Phase II Trial to Compare the Immunogenicity and Safety of a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE\u00ae (MVA-BN\u00ae) Smallpox Vaccine in Vaccinia-na\u00efve Healthy Subjects", 
        "overall_official": {
            "affiliation": "University of Kentucky", 
            "last_name": "Richard N Greenberg, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Geometric Mean Titers (GMTs) after two IMVAMUNE\u00ae FD or IMVAMUNE\u00ae LF vaccinations measured by vaccinia-specific ELISA at trial Visit 4 (Week 6).", 
            "measure": "Geometric Mean Titers (GMTs) measured by ELISA", 
            "safety_issue": "No", 
            "time_frame": "Visit 4 (Week 6)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01668537"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Occurrence, relationship to the trial vaccines and intensity of any Serious Adverse Event (SAE).", 
                "measure": "Serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Any Time"
            }, 
            {
                "description": "Occurrence, relationship to the trial vaccines and intensity of any Adverse Event of Special Interest (AESI)", 
                "measure": "Adverse Events of Special Interests", 
                "safety_issue": "Yes", 
                "time_frame": "Any Time"
            }, 
            {
                "description": "Occurrence of any Grade 3 or 4 Adverse Events (AEs) probably, possibly or definitely related to the trial vaccines within 28 days after each vaccination.", 
                "measure": "Grade 3 or 4 Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "28 days after vaccination"
            }, 
            {
                "description": "Occurrence, relationship to the trial vaccines and intensity of unsolicited non-serious AEs within 28 days after each vaccination", 
                "measure": "Unsolicited non-serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "28 days after vaccination"
            }, 
            {
                "description": "Occurrence, intensity and duration of solicited local AEs (redness, swelling, induration, pruritus and pain) during the 8-day period (day of vaccination and the following 7 days) after each vaccination", 
                "measure": "Solicited local Averse Events", 
                "safety_issue": "Yes", 
                "time_frame": "8 days after each vaccination"
            }, 
            {
                "description": "Occurrence, relationship to the trial vaccines, intensity and duration of solicited general AEs (pyrexia, headache, myalgia, nausea, fatigue and chills) during the 8-day period (day of vaccination and the following 7 days) after each vaccination", 
                "measure": "Solicited general AEs", 
                "safety_issue": "Yes", 
                "time_frame": "8 days after each vaccination"
            }, 
            {
                "description": "GMTs after two IMVAMUNE\u00ae FD or IMVAMUNE\u00ae LF vaccinations measured by vaccinia-specific PRNT at trial Visit 4 (Week 6).", 
                "measure": "GMTs measured by PRNT", 
                "safety_issue": "No", 
                "time_frame": "Visit 4 (Week 6)"
            }, 
            {
                "description": "Seroconversion rates after two IMVAMUNE\u00ae vaccinations measured by vaccinia-specific ELISA at trial Visit 4 (Week 6).", 
                "measure": "Seroconversion measured by ELISA", 
                "safety_issue": "No", 
                "time_frame": "Visit 4 (week 6)"
            }, 
            {
                "description": "Seroconversion rates after two IMVAMUNE\u00ae vaccinations measured by vaccinia-specific PRNT at trial Visit 4 (Week 6).", 
                "measure": "Seroconversion measured by PRNT", 
                "safety_issue": "No", 
                "time_frame": "Visit 4 (week 6)"
            }, 
            {
                "description": "GMTs and Seroconversion rates at all other immunogenicity sampling points as determined by vaccinia-specific ELISA and PRNT", 
                "measure": "GMTs and Seroconversion rates", 
                "safety_issue": "No", 
                "time_frame": "Any time"
            }, 
            {
                "description": "Response rates and magnitudes of response of IFN-\u03b3 producing T cells measured by vaccinia-specific Enzyme Linked Immuno Spot Technique (ELISPOT)", 
                "measure": "Response rates and magnitudes of response of IFN-\u03b3 producing T cells", 
                "safety_issue": "No", 
                "time_frame": "Any time"
            }, 
            {
                "description": "Pearson Correlation Coefficient between the ELISA titers and the PRNT titers at weeks 4, 6 and 8 based on the log10 transformed titer values", 
                "measure": "Pearson Correlation Coefficient", 
                "safety_issue": "No", 
                "time_frame": "Week 4, 6 and 8"
            }
        ], 
        "source": "Bavarian Nordic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bavarian Nordic", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}